Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca’s Imfinzi reduces risk of death by 32% in stage III lung cancer
Image: AstraZeneca’s Durvalumab reduced the risk of death by 32% in comparison to standard of care in the PACIFIC trial. Photo: courtesy of Astrazeneca.
Image: AstraZeneca’s Durvalumab reduced the risk of death by 32% in comparison to standard of care in the PACIFIC trial. Photo: courtesy of Astrazeneca.